What the Body Does to Foliglurax in Healthy Volunteers

Lundbeck

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: Foliglurax

Study type

Interventional

Funder types

Industry

Identifiers

NCT04002895

18154A

Details and patient eligibility

About

This study evaluates how the body takes up and gets rid of foliglurax after swallowing a liquid dose.

Full description

Six healthy men will swallow a liquid dose of 80 mg that is labelled with a small dose of radioactive tracer. Blood, urine and faeces will be collected to measure how much of the radioactivity gets into the blood stream and ends up in the urine and faeces. It is also measured how the body gets rid of the radioactivity and how quickly.

Enrollment

6 patients

Sex

Male

Ages

45 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy men with a body mass index (BMI) of 19-30 kg/m2 (inclusive), and with a body weight of minimum 60 kg at the Screening Visit.

Exclusion criteria

The subject has or has had any clinically significant immunological, cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal, neurological, or psychiatric disease or other major disorder.

Other inclusion and exclusion criteria may apply.